


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:09Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406477" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406477</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>neurrp</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurol Res Pract</journal-id><journal-id journal-id-type="iso-abbrev">Neurol Res Pract</journal-id><journal-id journal-id-type="pmc-domain-id">3953</journal-id><journal-id journal-id-type="pmc-domain">neurrp</journal-id><journal-title-group><journal-title>Neurological Research and Practice</journal-title></journal-title-group><issn pub-type="epub">2524-3489</issn><publisher><publisher-name>Deutsche Gesellschaft f&#252;r Neurologie e.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406477</article-id><article-id pub-id-type="pmcid-ver">PMC12406477.1</article-id><article-id pub-id-type="pmcaid">12406477</article-id><article-id pub-id-type="pmcaiid">12406477</article-id><article-id pub-id-type="pmid">40898371</article-id><article-id pub-id-type="doi">10.1186/s42466-025-00422-y</article-id><article-id pub-id-type="publisher-id">422</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Multidisciplinary inpatient care for Parkinson&#8217;s disease: a single-centre cohort study on improvements in gait, overall motor function, and quality of life</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kleinholdermann</surname><given-names initials="U">Urs</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>M&#252;gge</surname><given-names initials="FCJ">Felicitas C. J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carapezza</surname><given-names initials="T">Tiziano</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Decher</surname><given-names initials="L">Lukas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Timmermann</surname><given-names initials="L">Lars</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5403-1959</contrib-id><name name-style="western"><surname>Pedrosa</surname><given-names initials="DJ">David J.</given-names></name><address><email>david.pedrosa@staff.uni-marburg.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01rdrb571</institution-id><institution-id institution-id-type="GRID">grid.10253.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9756</institution-id><institution>Department of Neurology, </institution><institution>Philipps-University Marburg, </institution></institution-wrap>Biegenstra&#223;e 10, 35032 Marburg, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01rdrb571</institution-id><institution-id institution-id-type="GRID">grid.10253.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9756</institution-id><institution>Center of Mind, Brain and Behaviour, </institution><institution>Philipps-University Marburg, </institution></institution-wrap>Marburg, Germany </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>7</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">478312</issue-id><elocation-id>62</elocation-id><history><date date-type="received"><day>4</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="42466_2025_Article_422.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Parkinson&#8217;s disease (PD) multimodal complex treatment (PD-MCT) is an inpatient therapeutic programme specifically designed for patients exhibiting parkinsonian symptoms. Established in Germany, this comprehensive approach addresses the multifaceted challenges associated with the management of PD, particularly in advanced stages or when complications such as motor fluctuations, dyskinesia, or non-motor symptoms become pronounced. The programme integrates pharmacological optimization, physiotherapy, occupational therapy, speech therapy, and psychological support, among other complementary therapies, to enhance patient outcomes holistically. Despite its availability for seventeen years, only seven studies evaluating the effectiveness of PD-MCT have been conducted. In this study we evaluated the effects of PD-MCT with a special focus on gait, hypothesizing an improvement after the treatment.</p></sec><sec><title>Methods</title><p id="Par2">In this single-centre cohort study at a German university hospital we included patients with PD diagnosed by the Movement Disorder Society (MDS) criteria, aged 18&#8211;85 years, legal capacity to consent and admitted for treatment with PD-MCT. We assessed changes in motor and non-motor symptoms using Wilcoxon&#8217;s signed rank test on pre/post measurements of part III of the motor part of the MDS Unified Parkinson&#8217;s Disease Rating Scale (MDS-UPDRS), the Parkinson&#8217;s Disease Questionnaire (PDQ-39) and the Timed Up and Go Test (TUG). As a particular emphasis was placed on gait analysis we objectively measured gait throughout the treatment period using advanced mobile sensor technology and analysed gait speed, stride length and lift height using linear mixed effects models.</p></sec><sec><title>Results</title><p id="Par3">In our sample of 43 PD patients we found significant improvements in MDS-UPRDRS part III (V&#8201;=&#8201;679, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001), PDQ-39 (V&#8201;=&#8201;770, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and TUG (V&#8201;=&#8201;753.5, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) values. as well as in the assessed gait parameters gait speed (t&#8201;=&#8201;66.44, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), stride length (t&#8201;=&#8201;62.67, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and lift height (t&#8201;=&#8201;28.16, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p></sec><sec><title>Conclusions</title><p id="Par4">Our results underscore the added value of a multimodal inpatient approach, thereby supporting its role as a justified investment in the management of complex PD cases. This work contributes to the expanding body of evidence advocating for integrated, multidisciplinary care models in the treatment of neurodegenerative disorders.</p></sec><sec><title>Trial registration</title><p id="Par5">This study has not been registered.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s42466-025-00422-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Parkinson&#8217;s disease</kwd><kwd>Multidisciplinary care</kwd><kwd>Complex treatment</kwd><kwd>Wearables</kwd></kwd-group><funding-group><award-group><funding-source><institution>Philipps-Universit&#228;t Marburg (1009)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Deutsche Gesellschaft f&#252;r Neurologie e.V. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par6">Parkinson&#8217;s disease (PD) is the second most common neurodegenerative disorder, with its prevalence rising rapidly mainly due to demographic shifts [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The disease is characterised by a diverse array of symptoms. While motor symptoms such as bradykinesia, rigidity, and tremor are hallmark features, these are frequently accompanied by non-motor symptoms, including hyposmia, sleep disorders, affective disturbances, constipation, and autonomic dysregulation [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par7">Over the past several decades, the availability of symptomatic treatments for individuals with PD has expanded significantly [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Dopaminergic replacement therapies, including dopamine agonists and levodopa, remain the cornerstone of treatment, targeting one of the key pathological mechanisms by restoring depleted dopamine levels in the substantia nigra [<xref ref-type="bibr" rid="CR7">7</xref>]. Other pharmacological options, such as COMT inhibitors and monoamine oxidase inhibitors, may be considered to enhance dopamine availability in the synaptic cleft [<xref ref-type="bibr" rid="CR8">8</xref>]. Furthermore, advancements in pharmacokinetic formulations facilitate more consistent dopaminergic stimulation throughout the day, thereby improving symptom control. In addition to dopaminergic treatments, invasive therapies such as Deep Brain Stimulation (DBS) have emerged as valuable long-term options that address both motor and certain non-motor symptoms [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. Despite the growing array of treatment options, the complexity of managing PD exacerbates as the disease progresses. Personalised therapeutic strategies are often necessary, given the variability in symptom presentation and disease trajectory among patients.</p><p id="Par8">As PD progresses, the burden of symptoms intensifies, impairing daily functioning. Key indicators of advanced PD, include falls, delusions, hallucinations, cognitive decline, motor fluctuations, and levodopa-induced dyskinesias [<xref ref-type="bibr" rid="CR12">12</xref>], complications which contribute to increased frailty and mortality [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par9">Comorbidities further complicate the management of PD, constraining treatment options due to potential drug interactions and contraindications [<xref ref-type="bibr" rid="CR3">3</xref>]. Thus, specialised care for PD is essential. In principle, outpatient care remains the standard and preferred setting for developing personalised therapeutic strategies [<xref ref-type="bibr" rid="CR14">14</xref>]. Some circumstances in PD, like crisis events, motor fluctuations as well as the management of DBS treatment and non-motor symptoms, however, can make inpatient care necessary [<xref ref-type="bibr" rid="CR15">15</xref>]. For these indications, among others,</p><p id="Par10">the German healthcare system provides a specialised intervention known as Parkinson&#8217;s Multimodal Complex Treatment (PD-MCT) [<xref ref-type="bibr" rid="CR16">16</xref>] <sc>which is recommended by the German guidelines for PD</sc> [<xref ref-type="bibr" rid="CR17">17</xref>]. PD-MCT is a comprehensive treatment programme that most often spans a duration of fourteen days [<xref ref-type="bibr" rid="CR18">18</xref>] and is administered by an interdisciplinary team comprising professionals from diverse fields. This team includes physiotherapists, occupational therapists, speech and language therapists, music therapists, neuropsychologists, specialised nurses, and movement disorders specialists. At the onset of treatment, specific objectives are established for each patient on an individualised basis, with progress monitored through weekly interdisciplinary meetings. Health insurance providers acknowledge the elevated costs associated with PD-MCT and offer reimbursement for this treatment. Although the advantages of PD-MCT are readily apparent, empirical evidence validating its effectiveness in several observational studies has only recently begun to emerge. Research conducted by Heimrich and Prell indicates that PD-MCT leads to improvements in motor function [<xref ref-type="bibr" rid="CR19">19</xref>]. Additionally, Hartelt et al. reported that the motor enhancements resulting from PD-MCT persist for several weeks following hospital discharge [<xref ref-type="bibr" rid="CR20">20</xref>]. Wagner et al., however, reported that several quality of life-related parameters deteriorated again after initial improvement from PD-MCT over a period of nine months [<xref ref-type="bibr" rid="CR21">21</xref>]. In a study by Ziegler et al., which involved a substantial sample of 591 patients, an enhancement in activities of daily living (ADL) was identified, as evaluated by the MDS-UPDRS part II [<xref ref-type="bibr" rid="CR22">22</xref>]. Predictors of ADL improvements as well as improvements in gait were described by Oppermann et al. [<xref ref-type="bibr" rid="CR23">23</xref>]. Furthermore, Scherbaum et al. discovered not only improvements in motor symptoms but also more favourable scores on depression and quality of life assessments [<xref ref-type="bibr" rid="CR24">24</xref>]. Recent reviews corroborate the beneficial effects of PD-MCT [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] or the broader concept of multidisciplinary rehabilitation [<xref ref-type="bibr" rid="CR26">26</xref>] on both motor and non-motor symptoms. Also a review on multidisciplinary PD care in in- as well as outpatient settings confirmed positive results e.g. in QoL, motor scores, and non-motor symptoms in several randomised controlled trials [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par11">The present study aimed to evaluate the effectiveness of PD-MCT utilising standard clinical rating scales and questionnaires to assess motor function and overall well-being at both admission and discharge. For the first time, we integrated mobile electronic sensors to continuously monitor gait throughout the treatment period. This method capitalises on advancements in sensor technology, facilitating a more comprehensive evaluation of motor function, building upon prior research utilising a simplified two-sensor configuration [<xref ref-type="bibr" rid="CR28">28</xref>]. We hypothesised that clinical rating scale values and mobile sensor measurements would show an improvement over the course of PD-MCT. Furthermore, we conducted exploratory analyses in order to identify factors influencing PD-MCT outcomes which could guide and facilitate future research.</p></sec><sec id="Sec115"><title>Methods</title><p id="Par12">The study was conducted as a single-centre cohort study. It adhered to the Declaration of Helsinki and received approval from the Research Ethics Committee of the Philipps University, Germany (reference number 86/21). Written informed consent was obtained from all participants. The study has not been registered in a trial registry.</p><sec id="Sec217"><title>Sample</title><p id="Par13">Participants were patients diagnosed with PD based on the Movement Disorders Society criteria [<xref ref-type="bibr" rid="CR29">29</xref>], who were admitted for at least 14 days of PD-MCT, were aged 18&#8211;85 years, and had legal capacity to consent. Exclusion criteria for this study included atypical parkinsonism, lack of legal capacity, pregnancy, severe psychiatric or neurological conditions or sensory impairments affecting participation. Initially, patients using walking aids or with multiple recent falls were excluded, but this criterion was revised because of too many exclusions. Patients were recruited from the University Hospital of Marburg over a 20-month period beginning in January 2021. Based on power calculations conducted before study begin we aimed at including 50 participants while assuming a drop-out rate of 10%. Detailed sample characteristics are found in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.</p></sec><sec id="Sec219"><title>Procedure</title><p id="Par14">All patients participated in a comprehensive PD-MCT programme, which encompassed a broad spectrum of therapeutic interventions tailored to address the complex needs of individuals with PD. This programme offered at least 7.5&#160;h of a customised combination of speech therapy, occupational therapy, physiotherapy, music therapy, and specialised nursing care in consultation with a movement disorders specialist. The therapeutic regimen was customised for each patient, ensuring alignment with their specific needs and preferences. Additionally, medication regimens were regularly reviewed and optimised during daily consultations. For patients with deep brain stimulation (DBS), device settings were evaluated and adjusted as necessary to maximize therapeutic benefit.</p><p id="Par15">At the onset of PD-MCT, patients were equipped with the Mobile GaitLab system (Mobile (Portabiles HealthCare Technologies GmbH). The system consists of two compact, portable devices, each containing an inertial measurement unit (IMU) sensor, designed to be affixed to the shoes (see Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) as well as a smartphone application. Patients were instructed to independently attach the sensors and use the smartphone to start and stop the measurements daily, promoting an active role in their treatment process.</p><p id="Par16">To assess the programme&#8217;s impact on motor and non-motor symptoms, as well as overall patient satisfaction, participants completed standardised questionnaires and underwent comprehensive clinical evaluations at the first (or in some cases the second) and at the last day of the treatment period. This dual-assessment approach ensured a thorough evaluation of treatment outcomes, encompassing both subjective patient experiences and objective clinical measures.</p><p id="Par17">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Gait sensors affixed to both shoes of a person in the position used during measurements (reproduced from [<xref ref-type="bibr" rid="CR30">30</xref>])</p></caption><graphic id="d33e361" position="float" orientation="portrait" xlink:href="42466_2025_422_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec224"><title>Measures</title><p id="Par18">The impact of PD-MCT was evaluated using a combination of self-reported questionnaires, clinical assessments, and objective sensor-based measurements. Health-related quality of life was assessed pre- and post-treatment using the Parkinson&#8217;s Disease Questionnaire (PDQ-39) [<xref ref-type="bibr" rid="CR31">31</xref>], which captures eight critical domains: mobility, daily activities, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. Additionally, at the end of the treatment we assessed overall satisfaction with PD-MCT and subjective improvement in four domains we deemed to be highly relevant to PD patients: gait, agility, daily living and tremor. This was done using a custom-designed five-item self-rating scale, with responses ranging from zero (does not apply) to four (fully applies) points.</p><p id="Par19">Mobility was evaluated through two established clinical assessments: the Timed Up and Go (TUG) test [<xref ref-type="bibr" rid="CR32">32</xref>] and part III of the MDS-UPDRS scale [<xref ref-type="bibr" rid="CR33">33</xref>], which measures motor symptoms. To complement these clinical evaluations, gait was objectively assessed using the Mobile GaitLab system (Portabiles HealthCare Technologies GmbH), which employs IMU sensors to provide precise measurements. Key gait parameters, including speed, stride length, and maximum foot lift, were extracted using dynamic time warping techniques [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. These parameters were analyzed as primary indicators of gait quality, providing a comprehensive view of the programme&#8217;s impact on motor function [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec227"><title>Analyses</title><p id="Par20">Descriptive statistics were calculated for pre- and post-treatment measurements derived from the PDQ-39 data to assess the impact of PD-MCT on health-related quality of life. The differences between these measurements were evaluated to quantify the treatment effect, with statistical significance determined using Wilcoxon&#8217;s signed rank test. For the custom-designed short questionnaire, median response values were computed across the sample to summarise overall feedback.</p><p id="Par21">Clinical mobility metrics, including TUG and MDS-UPDRS part III scores, were also compared pre- and post-treatment using Wilcoxon&#8217;s signed rank test to identify significant changes. Gait parameters obtained from mobile sensor measurements were analysed using linear mixed models. This statistical approach allowed us to account for repeated measurements within subjects and to investigate the influence of medication adjustments on gait changes throughout the treatment period.</p><p id="Par22">After completing these planned comparisons, exploratory analyses were conducted, including correlational studies and group comparisons, guided by visual inspection of the data to identify factors influencing the results. Improvements in gait parameters were further analysed through individual linear regression models to examine potential predictors of change.</p><p id="Par23">All statistical analyses were performed using R (version 3.4.4) [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec></sec><sec id="Sec2"><title>Results</title><sec id="Sec232"><title>Participants</title><p id="Par24">A total of 45 patients (21 female) were recruited from the University Hospital of Marburg, with 43 completing the study over a 20-month period beginning in January 2021. Due to falls, we initially excluded 12 persons (cf. Methods section). After inclusion, one subject was excluded from the gait analysis due to a leg injury and three more because of technical issues with sensor recordings. One patient prematurely discontinued treatment after ten days but his data were kept for analysis. The average participant age was 65 years, with a median Hoehn &amp; Yahr score of 2 (IQR: 1). Detailed sample characteristics are found in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par25">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Sample characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">N</italic>
</th><th align="left" colspan="1" rowspan="1">43</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><p>age</p><p>
<italic toggle="yes">mean (sd)</italic>
</p></td><td align="left" colspan="1" rowspan="1">65.33 (8.62)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8205;sex (male / female)</td><td align="left" colspan="1" rowspan="1">22 / 21</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Hoehn &amp; Yahr stage</p><p>
<italic toggle="yes">median (IQR)</italic>
</p></td><td align="left" colspan="1" rowspan="1">2 (1)</td></tr><tr><td align="left" colspan="1" rowspan="1">H/Y 1</td><td align="left" colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">H/Y 2</td><td align="left" colspan="1" rowspan="1">24</td></tr><tr><td align="left" colspan="1" rowspan="1">H/Y 3</td><td align="left" colspan="1" rowspan="1">14</td></tr><tr><td align="left" colspan="1" rowspan="1">H/Y 4</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>time since PD diagnosis</p><p>in years <italic toggle="yes">mean (sd)</italic></p></td><td align="left" colspan="1" rowspan="1">10.42 (7.04)</td></tr><tr><td align="left" colspan="1" rowspan="1">treatment duration in days <italic toggle="yes">mean (sd)</italic></td><td align="left" colspan="1" rowspan="1">15.21 (1.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">patients treated with DBS</td><td align="left" colspan="1" rowspan="1">18</td></tr><tr><td align="left" colspan="1" rowspan="1">patients using walking aids</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">- walker</td><td align="left" colspan="1" rowspan="1">6</td></tr><tr><td align="left" colspan="1" rowspan="1">- stick</td><td align="left" colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">- crutches</td><td align="left" colspan="1" rowspan="1">1</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec235"><title>Main results</title><sec id="Sec3"><title>PDQ39</title><p id="Par26">Our analysis revealed a statistically significant improvement in the total PDQ-39SI score following PD-MCT. The magnitude of improvement was 4.672 points, representing a 15.7% reduction relative to the baseline pretest value. Significant improvements were also observed in the subscales of mobility, activities of daily living, stigma, and bodily discomfort (cf. Table&#160;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par27">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Pre/post PD-MCT comparison of clinical scales and LEDD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">pre PD-MCT<break/>mean (sd)</th><th align="left" colspan="1" rowspan="1">post PD-MCT<break/>mean (sd)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value<break/>(statistic)<sup>1</sup></th><th align="left" colspan="1" rowspan="1">effect size (<italic toggle="yes">r</italic>)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">MDS-UPDRS part III</td><td char="." align="char" colspan="1" rowspan="1">33.93 (15.51)</td><td char="." align="char" colspan="1" rowspan="1">28.65 (13.02)</td><td align="left" colspan="1" rowspan="1">0.001 (V&#8201;=&#8201;679)</td><td align="left" colspan="1" rowspan="1">0.496</td></tr><tr><td align="left" colspan="1" rowspan="1">TUG (s)</td><td char="." align="char" colspan="1" rowspan="1">13.39 (5.58)</td><td char="." align="char" colspan="1" rowspan="1">10.98 (4.59)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001 (V&#8201;=&#8201;753.5)</td><td align="left" colspan="1" rowspan="1">0.583</td></tr><tr><td align="left" colspan="1" rowspan="1">PDQ39 SI</td><td char="." align="char" colspan="1" rowspan="1">29.77 (12.29)</td><td char="." align="char" colspan="1" rowspan="1">25.09 (12.03)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001 (V&#8201;=&#8201;770)</td><td align="left" colspan="1" rowspan="1">0.547</td></tr><tr><td align="left" colspan="1" rowspan="1"> - mobility</td><td char="." align="char" colspan="1" rowspan="1">46.45 (22.44)</td><td char="." align="char" colspan="1" rowspan="1">36.74 (21.48)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001 (V&#8201;=&#8201;744.5)</td><td align="left" colspan="1" rowspan="1">0.621</td></tr><tr><td align="left" colspan="1" rowspan="1"> - activities</td><td char="." align="char" colspan="1" rowspan="1">29.26 (18.13)</td><td char="." align="char" colspan="1" rowspan="1">23.64 (16.41)</td><td align="left" colspan="1" rowspan="1">0.003 (V&#8201;=&#8201;573)</td><td align="left" colspan="1" rowspan="1">0.46</td></tr><tr><td align="left" colspan="1" rowspan="1"> - emotional wellbeing</td><td char="." align="char" colspan="1" rowspan="1">28.68 (17.75)</td><td char="." align="char" colspan="1" rowspan="1">25.58 (18.04)</td><td align="left" colspan="1" rowspan="1">0.593 (V&#8201;=&#8201;367.5)</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"> - stigma</td><td char="." align="char" colspan="1" rowspan="1">17.73 (23.22)</td><td char="." align="char" colspan="1" rowspan="1">13.66 (18.81)</td><td align="left" colspan="1" rowspan="1">0.031 (V&#8201;=&#8201;357)</td><td align="left" colspan="1" rowspan="1">0.373</td></tr><tr><td align="left" colspan="1" rowspan="1"> - social support</td><td char="." align="char" colspan="1" rowspan="1">18.22 (22.29)</td><td char="." align="char" colspan="1" rowspan="1">15.31 (17.05)</td><td align="left" colspan="1" rowspan="1">0.455 (V&#8201;=&#8201;163)</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"> - cognition</td><td char="." align="char" colspan="1" rowspan="1">34.59 (18.82)</td><td char="." align="char" colspan="1" rowspan="1">31.54 (18.19)</td><td align="left" colspan="1" rowspan="1">0.124 (V&#8201;=&#8201;498.5)</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"> - communication</td><td char="." align="char" colspan="1" rowspan="1">25.00 (21.21)</td><td char="." align="char" colspan="1" rowspan="1">24.81 (19.79)</td><td align="left" colspan="1" rowspan="1">0.802 (V&#8201;=&#8201;266)</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"> - bodily discomfort</td><td char="." align="char" colspan="1" rowspan="1">38.18 (19.01)</td><td char="." align="char" colspan="1" rowspan="1">29.46 (22.3)</td><td align="left" colspan="1" rowspan="1">0.007 (V&#8201;=&#8201;529)</td><td align="left" colspan="1" rowspan="1">0.447</td></tr><tr><td align="left" colspan="1" rowspan="1">LEDD</td><td char="." align="char" colspan="1" rowspan="1">872.5 (485.06)</td><td char="." align="char" colspan="1" rowspan="1">959.05 (555.59)</td><td align="left" colspan="1" rowspan="1">0.012 (V&#8201;=&#8201;185.5)</td><td align="left" colspan="1" rowspan="1">0.401</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup> Teststatistic V of Wilcoxon signed rank test</p></table-wrap-foot></table-wrap>
</p><p id="Par28">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Changes in health-related quality of life. The total score of the health-related quality of life (PDQ-39 SI) and its subscores are illustrated as means before (solid circles) and after (open circles) the intervention. Errorbars are two standard errors of the mean value. Statistically significant differences are marked by asterisks (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05: *, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01: **, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001: ***)</p></caption><graphic id="d33e727" position="float" orientation="portrait" xlink:href="42466_2025_422_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>Custom questionnaire for patient satisfaction</title><p id="Par29">Self-reported satisfaction with and improvement after PD-MCT treatment was high across all assessed domains (see Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). The median satisfaction scores were all at three out of four possible points.</p><p id="Par30">It is worth highlighting that the tremor domain exhibited greater variability in scores compared to other domains. This variability likely reflects the fact that tremor symptoms were present in only a subset of the patient sample, thereby influencing the overall results for this category.</p><p id="Par31">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Boxplot with individual (black dots, randomly jittered for visibility) and median (white diamonds) responses to the self-report questionnaire for satisfaction with PD-MCT and subjective improvement in four different domains after the treatment</p></caption><graphic id="d33e746" position="float" orientation="portrait" xlink:href="42466_2025_422_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec5"><title>Timed-up-and-go test (TUG)</title><p id="Par32">The mean time to complete the TUG decreased statistically significant by 2.406&#160;s of almost 18% between pre- and post-treatment measurements (cf. Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p></sec><sec id="Sec6"><title>MDS-UPDRS part III</title><p id="Par33">Motor symptoms, as assessed by the MDS-UPDRS part III, showed significant improvement after the treatment period. The mean score decreased by 5.286 points (16%) from the pre-treatment mean score (cf. Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) A visual comparison of pre- and post-treatment scores is provided in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>.</p><p id="Par34">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Violin of the MDS-UPDRS part III scores before and after treatment. The white dot represents the median, the black bar outlines the 25th -75th percentile. Statistical significance is marked by asterisks (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01: **)</p></caption><graphic id="d33e777" position="float" orientation="portrait" xlink:href="42466_2025_422_Fig4_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec245"><title>Gait analyses</title><p id="Par35">Significant improvements were observed in all three gait parameters over the treatment period. Linear mixed-effects regression analysis, with patient identity included as a random factor, showed that gait speed increased by 7.54&#160;cm/s (t&#8201;=&#8201;66.44, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Stride length also increased by 6.4&#160;cm over the course of the treatment (t&#8201;=&#8201;62.67, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Furthermore, lift height showed a statistically significant improvement, with an increase of 3.86&#160;mm over the same period (t&#8201;=&#8201;28.16, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). For a detailed visualization of the gait data and model predictions, please refer to Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>.</p><p id="Par36">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Results of the gait analysis over time. Per-patient averaged daily mean values for gait speed, stride length, and lift height, alongside fixed-effects predictions from linear mixed-effects models using treatment day as a predictor</p></caption><graphic id="d33e803" position="float" orientation="portrait" xlink:href="42466_2025_422_Fig5_HTML.jpg"/></fig>
</p></sec><sec id="Sec248"><title>Other analyses</title><p id="Par37">In our exploratory analyses of the effect of medication changes on outcome parameters, we found no significant Spearman rank correlations between pre/post-treatment differences in levodopa equivalent daily dose (LEDD) and the corresponding differences in PDQ-39 total scores, TUG test results, and MDS-UPDRS part III values (all <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05). When incorporating LEDD as an additional predictor alongside treatment duration in a linear mixed effects model, statistically significant positive effects of LEDD on all three gait parameters were found. However, the magnitude of these effects was minimal.</p><p id="Par38">For assessing demographics, we explored the influence of age, sex, Hoehn &amp; Yahr stage as well as PD duration and DBS treatment group.</p><p id="Par39">Patients treated with DBS reported higher satisfaction with PD-MCT scores compared to those without DBS. This trend was further supported in a subsample of 21 individuals (8 treated with DBS) who evaluated subjective tremor improvement, where DBS-treated patients again reported significantly higher improvement. Additionally, in the overall sample, male patients rated their subjective gait improvement higher than female patients.</p><p id="Par40">Higher Hoehn &amp; Yahr stages were significantly associated with greater pre/post-treatment improvements in both MDS-UPDRS part III scores and TUG test results. This relationship remained robust even when improvements were normalised by pre-treatment values, indicating that the observed effect is not merely attributable to a floor effect. Subjective treatment success, as measured by the &#8220;agility&#8221; scale, was positively correlated with objective improvements measured by slope coefficients of a per-individual linear regression of gait speed and stride length on treatment days. These findings suggest that perceived agility improvements align with measurable changes in mobility. A summary of all reported exploratory results is shown in supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>.</p></sec></sec><sec id="Sec7"><title>Discussion</title><p id="Par41">In this study, we analysed 43 PD patients undergoing PD-MCT, a German healthcare programme tailored for patients suffering from PD. Notably, this is the first study to employ continuous sensor-based gait measurements throughout treatment, providing detailed, objective insights into motor function. Beyond gait, we examined factors influencing symptom improvement, offering fresh perspectives on the effectiveness of this comprehensive treatment approach.</p><p id="Par42">Our findings highlight the significant benefits of PD-MCT across all measured outcomes. The PDQ-39 questionnaire showed a 15.7% improvement in quality of life post-treatment, exceeding the clinically significant threshold [<xref ref-type="bibr" rid="CR37">37</xref>] and aligning with prior studies [<xref ref-type="bibr" rid="CR24">24</xref>]. Improvements were most notable in mobility, activities of daily living, and bodily discomfort, likely due to targeted physical therapies. Interestingly, the stigma dimension also improved, possibly reflecting the normalising environment of the hospital. However, no significant changes were seen in cognition, social support, or communication, suggesting these areas may require longer-term interventions or enhancements to the PD-MCT programme. Importantly, improvements in PDQ-39 scores were unrelated to LEDD adjustments, underscoring the role of non-pharmacological interventions, such as physiotherapy and occupational therapy.</p><p id="Par43">Patient-reported outcomes further demonstrated high satisfaction with PD-MCT. Subjective improvements in daily living, agility, gait, and tremor closely mirrored objective results. These were supported by a 16% improvement in MDS-UPDRS part III scores and an 18% improvement in TUG performance, aligning with prior studies [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Our absolute improvement in UPDRS-III surpassed the clinically relevant threshold of 3.9 points [<xref ref-type="bibr" rid="CR38">38</xref>], achieved within a relatively short time. Similarly, TUG results paralleled previous findings, reinforcing the value of non-pharmacological therapies in PD-MCT&#8217;s success.</p><p id="Par44">For the first time, continuous sensor-based monitoring confirmed clinically meaningful improvements in gait parameters during treatment. Gait speed increased by 5.4&#160;cm/s over 14 days, consistent with earlier findings [<xref ref-type="bibr" rid="CR28">28</xref>]. Stride length and lift height also showed significant gains, with lift height being evaluated for the first time. While gait improvements correlated with LEDD changes, the effects were minor in size, highlighting the primary role of non-pharmacological interventions in driving these outcomes.</p><p id="Par45">In summary, PD-MCT effectively improves symptoms across subjective, clinical, and objective measures. Post-hoc analyses revealed higher satisfaction among DBS-treated patients, particularly for tremor, and greater gait satisfaction in males, though the reasons remain unclear. Advanced disease stages showed larger clinical motor improvements, possibly due to earlier stages being adequately managed in outpatient settings. While no predictors of individual gait improvements were identified, gait changes correlated with perceived agility, suggesting a broader impact on lower-body mobility.</p><p id="Par46">Our data emphasises the benefit of a multiprofessional approach to manage PD&#8217;s complex symptoms. This is evident in the independence of improvements from LEDD changes and the critical role of gait as a marker of quality of life [<xref ref-type="bibr" rid="CR39">39</xref>&#8211;<xref ref-type="bibr" rid="CR41">41</xref>]. Improving gait must remain a priority in PD treatment. Continuous monitoring, such as IMU-based assessments, offers an accessible and scalable solution for tracking gait and motor symptoms. Our study confirms the feasibility of integrating these technologies in hospital settings, complementing previous outpatient-focused research [<xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par47">This study&#8217;s design as a single-centre cohort study imposes limitations. The lack of a control group increases the risk of bias from uncontrolled confounding variables or biased patient selection. Additionally, the single-centre design may limit generalisability, particularly given the relatively high proportion of DBS-treated patients in our sample. Furthermore, while we assessed the influence of LEDD in our analyses, we could not explore the effects of DBS adjustments, as patients could change stimulation programs and amplitude independently and exact timing of such changes was unavailable. Finally, testing multiple outcome parameters increases the risk of type I errors. For future research, we recommend that multicentre studies and randomised controlled trials be conducted to reduce bias and enhance generalisability. Such studies should also quantify non-pharmocological therapies in order to assess their effects. Another suggestion would be that analyses of insurance claims could be undertaken to measure the effect of PD-MCT on e.g. falls or re-hospitalisation.</p></sec><sec id="Sec8"><title>Conclusions</title><p id="Par48">PD-MCT is a highly effective treatment within the German healthcare system, significantly improving multiple symptom domains, especially gait, for PD patients. Its benefits extend beyond medication adjustments, highlighting the value of non-pharmacological therapies. The programme&#8217;s comprehensive, multidisciplinary nature, in our opinion, justifies its cost and underscores the importance of holistic care in managing this complex disease. Based on our findings, we feel that multimodal treatment models should be more widely implemented and made more accessible within routine care to further enhance patient outcomes and quality of life.</p></sec><sec id="Sec81" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="42466_2025_422_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank all participating patients for their generous donation of their data. We thank Stefanie Spriewald, study coordinator at Marburg University Hospital for the support in acquiring the sample and Annika Nonnenmann for helping out with Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. Additionally, we would like to thank Portabiles HealthCare Technologies GmbH and especially Julius Hannink and Malte Ollenschl&#228;ger for their support.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Urs Kleinholdermann: study design, data analysis, wrote article. Felicitas M&#252;gge: study design, reviewed article. Lukas Decher: data acquisition, data analysis, reviewed article. Tiziano Carapezza: data acquisition, data analysis, reviewed article. Lars Timmermann: data acquisition, review article. David Pedrosa: study design, data analysis, wrote article.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL. This study was supported by the International Parkinson&#8217;s Foundation. The sensors used, a medical device, were provided by Portabiles Healthcare GmbH.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The code used for the statistical analysis is available at: <ext-link ext-link-type="uri" xlink:href="https://github.com/kleinholdermann/pd_gait_pkb">https://github.com/kleinholdermann/pd_gait_pkb</ext-link> Pseudonymised data are available from the authors upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par49">The study adhered to the Declaration of Helsinki and received approval from the Research Ethics Committee of the Philipps University, Germany (reference number 86/21).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par50">Written informed consent was obtained from all participants.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par51">Urs Kleinholdermann, Lukas Decher, Tiziano Carapezza and Felicitas M&#252;gge have no competing interests to report. Lars Timmermann LT has received payments as a consultant for Boston Scientific; honoraria as a speaker on symposia sponsored by UCB, Desitin, Boston Scientific, AbbVie, Novartis, GlaxoSmithKline, Neuraxpharm, Teva, the Movement Disorders Society und DIAPLAN. The institution of LT, not LT personally, received funding by Boston Scientific, the German Research Foundation, the German Ministry of Education and Research, the Otto Loewi Foundation and the Deutsche Parkinson Vereinigung, outside the submitted work. Neither LT nor any member of his family holds stocks, stock options, patents or financial interests in any of the above-mentioned companies or their competitors. LT serves as the president of the German Neurological Society without any payment or any income. David Pedrosa received honoraria as a speaker at symposia sponsored by AbbVie Inc., Bayer, Bial, Boston Scientific Corp., Esteve Pharmaceuticals, Medtronic and Zambon. He received consultancy fees from AbbVie Inc., Bial, Boston Scientific Corp., Bayer, and Desitin, and he was awarded a scientific grant from Boston Scientific Corp. for a project entitled &#8220;Sensor-based Optimization of Deep Brain Stimulation Settings in Parkinson&#8217;s Disease&#8221; (COMPARE-DBS: Computerized Parameter Optimization of Deep Brain Stimulation in Idiopathic Parkinson&#8217;s Syndrome). Lastly, David Pedrosa had his travel expenses reimbursed by Bial, Desitin, Esteve Pharmaceuticals GmbH, and Boston Scientific Corp. for conference participation.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorsey</surname><given-names>ER</given-names></name><name name-style="western"><surname>Bloem</surname><given-names>BR</given-names></name></person-group><article-title>The Parkinson Pandemic&#8212;A call to action</article-title><source>JAMA Neurology</source><year>2018</year><volume>75</volume><issue>1</issue><fpage>9</fpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2017.3299</pub-id><pub-id pub-id-type="pmid">29131880</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Dorsey, E. R., &amp; Bloem, B. R. (2018). The Parkinson pandemic&#8212;A call to action. <italic toggle="yes">JAMA Neurology</italic>, <italic toggle="yes">75</italic>(1), 9. 10.1001/jamaneurol.2017.3299<pub-id pub-id-type="pmid">29131880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2017.3299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloem</surname><given-names>BR</given-names></name><name name-style="western"><surname>Okun</surname><given-names>MS</given-names></name><name name-style="western"><surname>Klein</surname><given-names>C</given-names></name></person-group><article-title>Parkinson&#8217;s disease</article-title><source>The Lancet</source><year>2021</year><volume>397</volume><issue>10291</issue><fpage>2284</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00218-X</pub-id><pub-id pub-id-type="pmid">33848468</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Bloem, B. R., Okun, M. S., &amp; Klein, C. (2021). Parkinson&#8217;s disease. <italic toggle="yes">The Lancet</italic>, <italic toggle="yes">397</italic>(10291), 2284&#8211;2303. 10.1016/S0140-6736(21)00218-X<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00218-X</pub-id><pub-id pub-id-type="pmid">33848468</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weerkamp</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Tissingh</surname><given-names>G</given-names></name><name name-style="western"><surname>Poels</surname><given-names>PJE</given-names></name><name name-style="western"><surname>Zuidema</surname><given-names>SU</given-names></name><name name-style="western"><surname>Munneke</surname><given-names>M</given-names></name><name name-style="western"><surname>Koopmans</surname><given-names>RT</given-names></name><name name-style="western"><surname>C</surname></name><name name-style="western"><surname>M</surname></name><name name-style="western"><surname>Bloem</surname><given-names>BR</given-names></name></person-group><article-title>Nonmotor symptoms in nursing home residents with parkinson&#8217;s disease: Prevalence and effect on quality of life</article-title><source>Journal of the American Geriatrics Society</source><year>2013</year><volume>61</volume><issue>10</issue><fpage>1714</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1111/jgs.12458</pub-id><pub-id pub-id-type="pmid">24117286</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Weerkamp, N. J., Tissingh, G., Poels, P. J. E., Zuidema, S. U., Munneke, M., Koopmans, R. T., C., M., &amp; Bloem, B. R. (2013). Nonmotor symptoms in nursing home residents with parkinson&#8217;s disease: Prevalence and effect on quality of life. <italic toggle="yes">Journal of the American Geriatrics Society</italic>, <italic toggle="yes">61</italic>(10), 1714&#8211;1721. 10.1111/jgs.12458<pub-id pub-id-type="pmid">24117286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgs.12458</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Kumaresan, M., &amp; Khan, S. (2021). Spectrum of Non-Motor symptoms in parkinson&#8217;s disease. Cureus. 10.7759/cureus.13275<pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.13275</pub-id><pub-id pub-id-type="pmcid">PMC7949722</pub-id><pub-id pub-id-type="pmid">33728210</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cotzias</surname><given-names>GC</given-names></name><name name-style="western"><surname>Van Woert</surname><given-names>MH</given-names></name><name name-style="western"><surname>Schiffer</surname><given-names>LM</given-names></name></person-group><article-title>Aromatic amino acids and modification of parkinsonism</article-title><source>New England Journal of Medicine</source><year>1967</year><volume>276</volume><issue>7</issue><fpage>374</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1056/NEJM196702162760703</pub-id><pub-id pub-id-type="pmid">5334614</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Cotzias, G. C., Van Woert, M. H., &amp; Schiffer, L. M. (1967). Aromatic amino acids and modification of parkinsonism. <italic toggle="yes">New England Journal of Medicine</italic>, <italic toggle="yes">276</italic>(7), 374&#8211;379. 10.1056/NEJM196702162760703<pub-id pub-id-type="pmid">5334614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM196702162760703</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calne</surname><given-names>DB</given-names></name><name name-style="western"><surname>Teychenne</surname><given-names>PF</given-names></name><name name-style="western"><surname>Claveria</surname><given-names>LE</given-names></name><name name-style="western"><surname>Eastman</surname><given-names>R</given-names></name><name name-style="western"><surname>Greenacre</surname><given-names>JK</given-names></name><name name-style="western"><surname>Petrie</surname><given-names>A</given-names></name></person-group><source>Bromocriptine in Parkinsonism BMJ</source><year>1974</year><volume>4</volume><issue>5942</issue><fpage>442</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1136/bmj.4.5942.442</pub-id><pub-id pub-id-type="pmid">4425916</pub-id><pub-id pub-id-type="pmcid">PMC1612580</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastman, R., Greenacre, J. K., &amp; Petrie, A. (1974). <italic toggle="yes">Bromocriptine in Parkinsonism BMJ</italic>, <italic toggle="yes">4</italic>(5942), 442&#8211;444. 10.1136/bmj.4.5942.442<pub-id pub-id-type="pmid">4425916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.4.5942.442</pub-id><pub-id pub-id-type="pmcid">PMC1612580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pringsheim</surname><given-names>T</given-names></name><name name-style="western"><surname>Day</surname><given-names>GS</given-names></name><name name-style="western"><surname>Smith</surname><given-names>DB</given-names></name><name name-style="western"><surname>Rae-Grant</surname><given-names>A</given-names></name><name name-style="western"><surname>Licking</surname><given-names>N</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>MJ</given-names></name><name name-style="western"><surname>De Bie</surname><given-names>RMA</given-names></name><name name-style="western"><surname>Roze</surname><given-names>E</given-names></name><name name-style="western"><surname>Miyasaki</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>RA</given-names></name><name name-style="western"><surname>Espay</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Martello</surname><given-names>JP</given-names></name><name name-style="western"><surname>Gurwell</surname><given-names>JA</given-names></name><name name-style="western"><surname>Billinghurst</surname><given-names>L</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>K</given-names></name><name name-style="western"><surname>Fitts</surname><given-names>MS</given-names></name><name name-style="western"><surname>Cothros</surname><given-names>N</given-names></name><name name-style="western"><surname>Hall</surname><given-names>DA</given-names></name><name name-style="western"><surname>Rafferty</surname><given-names>M</given-names></name><name name-style="western"><surname>Lang</surname><given-names>AE</given-names></name></person-group><article-title>Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: A report of the AAN guideline subcommittee</article-title><source>Neurology</source><year>2021</year><volume>97</volume><issue>20</issue><fpage>942</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000012868</pub-id><pub-id pub-id-type="pmid">34782410</pub-id><pub-id pub-id-type="pmcid">PMC8672433</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Pringsheim, T., Day, G. S., Smith, D. B., Rae-Grant, A., Licking, N., Armstrong, M. J., De Bie, R. M. A., Roze, E., Miyasaki, J. M., Hauser, R. A., Espay, A. J., Martello, J. P., Gurwell, J. A., Billinghurst, L., Sullivan, K., Fitts, M. S., Cothros, N., Hall, D. A., Rafferty, M., &amp; Lang, A. E. (2021). Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: A report of the AAN guideline subcommittee. <italic toggle="yes">Neurology</italic>, <italic toggle="yes">97</italic>(20), 942&#8211;957. 10.1212/WNL.0000000000012868<pub-id pub-id-type="pmid">34782410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000012868</pub-id><pub-id pub-id-type="pmcid">PMC8672433</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tetrud</surname><given-names>JW</given-names></name><name name-style="western"><surname>Langston</surname><given-names>JW</given-names></name></person-group><article-title>The effect of deprenyl (Selegiline) on the natural history of parkinson&#8217;s disease</article-title><source>Science</source><year>1989</year><volume>245</volume><issue>4917</issue><fpage>519</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1126/science.2502843</pub-id><pub-id pub-id-type="pmid">2502843</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Tetrud, J. W., &amp; Langston, J. W. (1989). The effect of deprenyl (Selegiline) on the natural history of parkinson&#8217;s disease. <italic toggle="yes">Science</italic>, <italic toggle="yes">245</italic>(4917), 519&#8211;522. 10.1126/science.2502843<pub-id pub-id-type="pmid">2502843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.2502843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurtis</surname><given-names>MM</given-names></name><name name-style="western"><surname>Rajah</surname><given-names>T</given-names></name><name name-style="western"><surname>Delgado</surname><given-names>LF</given-names></name><name name-style="western"><surname>Dafsari</surname><given-names>HS</given-names></name></person-group><article-title>The effect of deep brain stimulation on the non-motor symptoms of parkinson&#8217;s disease: A critical review of the current evidence</article-title><source>Npj Parkinson&#8217;s Disease</source><year>2017</year><volume>3</volume><issue>1</issue><fpage>16024</fpage><pub-id pub-id-type="doi">10.1038/npjparkd.2016.24</pub-id><pub-id pub-id-type="pmid">28725706</pub-id><pub-id pub-id-type="pmcid">PMC5516616</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Kurtis, M. M., Rajah, T., Delgado, L. F., &amp; Dafsari, H. S. (2017). The effect of deep brain stimulation on the non-motor symptoms of parkinson&#8217;s disease: A critical review of the current evidence. <italic toggle="yes">Npj Parkinson&#8217;s Disease</italic>, <italic toggle="yes">3</italic>(1), 16024. 10.1038/npjparkd.2016.24<pub-id pub-id-type="pmid">28725706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npjparkd.2016.24</pub-id><pub-id pub-id-type="pmcid">PMC5516616</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Limousin</surname><given-names>P</given-names></name><name name-style="western"><surname>Foltynie</surname><given-names>T</given-names></name></person-group><article-title>Long-term outcomes of deep brain stimulation in Parkinson disease</article-title><source>Nature Reviews Neurology</source><year>2019</year><volume>15</volume><issue>4</issue><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/s41582-019-0145-9</pub-id><pub-id pub-id-type="pmid">30778210</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Limousin, P., &amp; Foltynie, T. (2019). Long-term outcomes of deep brain stimulation in Parkinson disease. <italic toggle="yes">Nature Reviews Neurology</italic>, <italic toggle="yes">15</italic>(4), 234&#8211;242. 10.1038/s41582-019-0145-9<pub-id pub-id-type="pmid">30778210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-019-0145-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benabid</surname><given-names>AL</given-names></name><name name-style="western"><surname>Pollak</surname><given-names>P</given-names></name><name name-style="western"><surname>Louveau</surname><given-names>A</given-names></name><name name-style="western"><surname>Henry</surname><given-names>S</given-names></name><name name-style="western"><surname>De Rougemont</surname><given-names>J</given-names></name></person-group><article-title>Combined (Thalamotomy and Stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease</article-title><source>Stereotactic and Functional Neurosurgery</source><year>1987</year><volume>50</volume><issue>1&#8211;6</issue><fpage>344</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1159/000100803</pub-id><pub-id pub-id-type="pmid">3329873</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Benabid, A. L., Pollak, P., Louveau, A., Henry, S., &amp; De Rougemont, J. (1987). Combined (Thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. <italic toggle="yes">Stereotactic and Functional Neurosurgery</italic>, <italic toggle="yes">50</italic>(1&#8211;6), 344&#8211;346. 10.1159/000100803<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000100803</pub-id><pub-id pub-id-type="pmid">3329873</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonini</surname><given-names>A</given-names></name><name name-style="western"><surname>Stoessl</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kleinman</surname><given-names>LS</given-names></name><name name-style="western"><surname>Skalicky</surname><given-names>AM</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>TS</given-names></name><name name-style="western"><surname>Sail</surname><given-names>KR</given-names></name><name name-style="western"><surname>Onuk</surname><given-names>K</given-names></name><name name-style="western"><surname>Odin</surname><given-names>PLA</given-names></name></person-group><article-title>Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced parkinson&#8217;s disease: A multi-country Delphi-panel approach</article-title><source>Current Medical Research and Opinion</source><year>2018</year><volume>34</volume><issue>12</issue><fpage>2063</fpage><lpage>2073</lpage><pub-id pub-id-type="doi">10.1080/03007995.2018.1502165</pub-id><pub-id pub-id-type="pmid">30016901</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Antonini, A., Stoessl, A. J., Kleinman, L. S., Skalicky, A. M., Marshall, T. S., Sail, K. R., Onuk, K., &amp; Odin, P. L. A. (2018). Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced parkinson&#8217;s disease: A multi-country Delphi-panel approach. <italic toggle="yes">Current Medical Research and Opinion</italic>, <italic toggle="yes">34</italic>(12), 2063&#8211;2073. 10.1080/03007995.2018.1502165<pub-id pub-id-type="pmid">30016901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03007995.2018.1502165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>MC</given-names></name><name name-style="western"><surname>Dalen</surname><given-names>I</given-names></name><name name-style="western"><surname>Maple-Gr&#248;dem</surname><given-names>J</given-names></name><name name-style="western"><surname>Tysnes</surname><given-names>OB</given-names></name><name name-style="western"><surname>Alves</surname><given-names>G</given-names></name></person-group><article-title>Parkinson&#8217;s disease clinical milestones and mortality</article-title><source>Npj Parkinson&#8217;s Disease</source><year>2022</year><volume>8</volume><issue>1</issue><fpage>58</fpage><pub-id pub-id-type="doi">10.1038/s41531-022-00320-z</pub-id><pub-id pub-id-type="pmid">35550520</pub-id><pub-id pub-id-type="pmcid">PMC9098431</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Gonzalez, M. C., Dalen, I., Maple-Gr&#248;dem, J., Tysnes, O. B., &amp; Alves, G. (2022). Parkinson&#8217;s disease clinical milestones and mortality. <italic toggle="yes">Npj Parkinson&#8217;s Disease</italic>, <italic toggle="yes">8</italic>(1), 58. 10.1038/s41531-022-00320-z<pub-id pub-id-type="pmid">35550520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-022-00320-z</pub-id><pub-id pub-id-type="pmcid">PMC9098431</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloem</surname><given-names>BR</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Dorsey</surname><given-names>ER</given-names></name><name name-style="western"><surname>Okun</surname><given-names>MS</given-names></name><name name-style="western"><surname>Okubadejo</surname><given-names>N</given-names></name><name name-style="western"><surname>Chan</surname><given-names>P</given-names></name><name name-style="western"><surname>Andrejack</surname><given-names>J</given-names></name><name name-style="western"><surname>Darweesh</surname><given-names>SKL</given-names></name><name name-style="western"><surname>Munneke</surname><given-names>M</given-names></name></person-group><article-title>Integrated and patient-centred management of parkinson&#8217;s disease: A network model for reshaping chronic neurological care</article-title><source>The Lancet Neurology</source><year>2020</year><volume>19</volume><issue>7</issue><fpage>623</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(20)30064-8</pub-id><pub-id pub-id-type="pmid">32464101</pub-id><pub-id pub-id-type="pmcid">PMC9671491</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Bloem, B. R., Henderson, E. J., Dorsey, E. R., Okun, M. S., Okubadejo, N., Chan, P., Andrejack, J., Darweesh, S. K. L., &amp; Munneke, M. (2020). Integrated and patient-centred management of parkinson&#8217;s disease: A network model for reshaping chronic neurological care. <italic toggle="yes">The Lancet Neurology</italic>, <italic toggle="yes">19</italic>(7), 623&#8211;634. 10.1016/S1474-4422(20)30064-8<pub-id pub-id-type="pmid">32464101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30064-8</pub-id><pub-id pub-id-type="pmcid">PMC9671491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scherbaum</surname><given-names>R</given-names></name><name name-style="western"><surname>T&#246;nges</surname><given-names>L</given-names></name></person-group><article-title>Multidisziplin&#228;re komplextherapie der Parkinson-Krankheit: Eckpfeiler einer individualisierten behandlung</article-title><source>Der Nervenarzt</source><year>2024</year><volume>95</volume><issue>8</issue><fpage>704</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1007/s00115-024-01666-w</pub-id><pub-id pub-id-type="pmid">38755423</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Scherbaum, R., &amp; T&#246;nges, L. (2024). Multidisziplin&#228;re komplextherapie der Parkinson-Krankheit: Eckpfeiler einer individualisierten behandlung. <italic toggle="yes">Der Nervenarzt</italic>, <italic toggle="yes">95</italic>(8), 704&#8211;713. 10.1007/s00115-024-01666-w<pub-id pub-id-type="pmid">38755423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00115-024-01666-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knop</surname><given-names>M</given-names></name><name name-style="western"><surname>S&#228;mann</surname><given-names>PG</given-names></name><name name-style="western"><surname>Keck</surname><given-names>ME</given-names></name></person-group><article-title>Parkinson-Komplextherapie am Max-Planck-Institut f&#252;r psychiatrie: Ein multimodales, flexibles Station&#228;res therapieprogramm f&#252;r kritische krankheitsphasen</article-title><source>Psychiatr Neurol</source><year>2017</year><volume>5</volume><fpage>24</fpage><lpage>29</lpage></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Knop, M., S&#228;mann, P. G., &amp; Keck, M. E. (2017). Parkinson-Komplextherapie am Max-Planck-Institut f&#252;r psychiatrie: Ein multimodales, flexibles Station&#228;res therapieprogramm f&#252;r kritische krankheitsphasen. <italic toggle="yes">Psychiatr Neurol</italic>, <italic toggle="yes">5</italic>, 24&#8211;29.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">H&#246;glinger, G., German Parkinson&#8217;s Guidelines Committee, &amp; Trenkwalder, C. (2024). Diagnosis and treatment of Parkinson&#180;s disease (guideline of the German Society for Neurology). <italic toggle="yes">Neurological research and practice</italic>, <italic toggle="yes">6</italic>(1), 30. 10.1186/s42466-024-00325-4<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s42466-024-00325-4</pub-id><pub-id pub-id-type="pmcid">PMC11157782</pub-id><pub-id pub-id-type="pmid">38845028</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richter</surname><given-names>D</given-names></name><name name-style="western"><surname>Bartig</surname><given-names>D</given-names></name><name name-style="western"><surname>Muhlack</surname><given-names>S</given-names></name><name name-style="western"><surname>Hartelt</surname><given-names>E</given-names></name><name name-style="western"><surname>Scherbaum</surname><given-names>R</given-names></name><name name-style="western"><surname>Katsanos</surname><given-names>AH</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>T</given-names></name><name name-style="western"><surname>Jost</surname><given-names>W</given-names></name><name name-style="western"><surname>Ebersbach</surname><given-names>G</given-names></name><name name-style="western"><surname>Gold</surname><given-names>R</given-names></name><name name-style="western"><surname>Krogias</surname><given-names>C</given-names></name><name name-style="western"><surname>T&#246;nges</surname><given-names>L</given-names></name></person-group><article-title>Dynamics of parkinson&#8217;s disease multimodal complex treatment in Germany from 2010<sup>&#8211;</sup>2016: Patient characteristics, access to treatment, and formation of regional centers</article-title><source>Cells</source><year>2019</year><volume>8</volume><issue>2</issue><fpage>151</fpage><pub-id pub-id-type="doi">10.3390/cells8020151</pub-id><pub-id pub-id-type="pmid">30754730</pub-id><pub-id pub-id-type="pmcid">PMC6406830</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Richter, D., Bartig, D., Muhlack, S., Hartelt, E., Scherbaum, R., Katsanos, A. H., M&#252;ller, T., Jost, W., Ebersbach, G., Gold, R., Krogias, C., &amp; T&#246;nges, L. (2019). Dynamics of parkinson&#8217;s disease multimodal complex treatment in Germany from 2010<sup>&#8211;</sup>2016: Patient characteristics, access to treatment, and formation of regional centers. <italic toggle="yes">Cells</italic>, <italic toggle="yes">8</italic>(2), 151. 10.3390/cells8020151<pub-id pub-id-type="pmid">30754730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells8020151</pub-id><pub-id pub-id-type="pmcid">PMC6406830</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heimrich</surname><given-names>KG</given-names></name><name name-style="western"><surname>Prell</surname><given-names>T</given-names></name></person-group><article-title>Short- and Long-Term effect of parkinson&#8217;s disease multimodal complex treatment</article-title><source>Brain Sciences</source><year>2021</year><volume>11</volume><issue>11</issue><fpage>1460</fpage><pub-id pub-id-type="doi">10.3390/brainsci11111460</pub-id><pub-id pub-id-type="pmid">34827459</pub-id><pub-id pub-id-type="pmcid">PMC8615811</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Heimrich, K. G., &amp; Prell, T. (2021). Short- and long-term effect of parkinson&#8217;s disease multimodal complex treatment. <italic toggle="yes">Brain Sciences</italic>, <italic toggle="yes">11</italic>(11), 1460. 10.3390/brainsci11111460<pub-id pub-id-type="pmid">34827459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci11111460</pub-id><pub-id pub-id-type="pmcid">PMC8615811</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartelt</surname><given-names>E</given-names></name><name name-style="western"><surname>Scherbaum</surname><given-names>R</given-names></name><name name-style="western"><surname>Kinkel</surname><given-names>M</given-names></name><name name-style="western"><surname>Gold</surname><given-names>R</given-names></name><name name-style="western"><surname>Muhlack</surname><given-names>S</given-names></name><name name-style="western"><surname>T&#246;nges</surname><given-names>L</given-names></name></person-group><article-title>Parkinson&#8217;s disease multimodal complex treatment (PD-MCT): Analysis of therapeutic effects and predictors for improvement</article-title><source>Journal of Clinical Medicine</source><year>2020</year><volume>9</volume><issue>6</issue><fpage>1874</fpage><pub-id pub-id-type="doi">10.3390/jcm9061874</pub-id><pub-id pub-id-type="pmid">32560079</pub-id><pub-id pub-id-type="pmcid">PMC7356837</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hartelt, E., Scherbaum, R., Kinkel, M., Gold, R., Muhlack, S., &amp; T&#246;nges, L. (2020). Parkinson&#8217;s disease multimodal complex treatment (PD-MCT): Analysis of therapeutic effects and predictors for improvement. <italic toggle="yes">Journal of Clinical Medicine</italic>, <italic toggle="yes">9</italic>(6), 1874. 10.3390/jcm9061874<pub-id pub-id-type="pmid">32560079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm9061874</pub-id><pub-id pub-id-type="pmcid">PMC7356837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>L</given-names></name><name name-style="western"><surname>Hauptmann</surname><given-names>B</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>AK</given-names></name><name name-style="western"><surname>Jochems</surname><given-names>N</given-names></name><name name-style="western"><surname>Schmeier</surname><given-names>B</given-names></name><name name-style="western"><surname>Schrader</surname><given-names>A</given-names></name><name name-style="western"><surname>Kohlmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Deck</surname><given-names>R</given-names></name></person-group><article-title>Evaluation of an individualized, tablet-based physiotherapy training programme for patients with parkinson&#8217;s disease: The ParkProTrain study, a quasi-randomised controlled trial</article-title><source>BMC Neurology</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>176</fpage><pub-id pub-id-type="doi">10.1186/s12883-022-02647-9</pub-id><pub-id pub-id-type="pmid">35568805</pub-id><pub-id pub-id-type="pmcid">PMC9106978</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Wagner, L., Hauptmann, B., Hoffmann, A. K., Jochems, N., Schmeier, B., Schrader, A., Kohlmann, T., &amp; Deck, R. (2022). Evaluation of an individualized, tablet-based physiotherapy training programme for patients with parkinson&#8217;s disease: The ParkProTrain study, a quasi-randomised controlled trial. <italic toggle="yes">BMC Neurology</italic>, <italic toggle="yes">22</italic>(1), 176. 10.1186/s12883-022-02647-9<pub-id pub-id-type="pmid">35568805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12883-022-02647-9</pub-id><pub-id pub-id-type="pmcid">PMC9106978</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziegler</surname><given-names>K</given-names></name><name name-style="western"><surname>Messner</surname><given-names>M</given-names></name><name name-style="western"><surname>Paulig</surname><given-names>M</given-names></name><name name-style="western"><surname>Starrost</surname><given-names>K</given-names></name><name name-style="western"><surname>Reuschenbach</surname><given-names>B</given-names></name><name name-style="western"><surname>Fietzek</surname><given-names>UM</given-names></name><name name-style="western"><surname>Ceballos-Baumann</surname><given-names>AO</given-names></name></person-group><article-title>Activities of daily living are improved by inpatient multimodal complex treatment for PD&#8212;A Real&#8208;World cohort study</article-title><source>Movement Disorders Clinical Practice</source><year>2023</year><volume>10</volume><issue>1</issue><fpage>42</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/mdc3.13578</pub-id><pub-id pub-id-type="pmid">36698998</pub-id><pub-id pub-id-type="pmcid">PMC9847313</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Ziegler, K., Messner, M., Paulig, M., Starrost, K., Reuschenbach, B., Fietzek, U. M., &amp; Ceballos-Baumann, A. O. (2023). Activities of daily living are improved by inpatient multimodal complex treatment for PD&#8212;A real&#8208;world cohort study. <italic toggle="yes">Movement Disorders Clinical Practice</italic>, <italic toggle="yes">10</italic>(1), 42&#8211;54. 10.1002/mdc3.13578<pub-id pub-id-type="pmid">36698998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mdc3.13578</pub-id><pub-id pub-id-type="pmcid">PMC9847313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oppermann</surname><given-names>J</given-names></name><name name-style="western"><surname>Tschentscher</surname><given-names>V</given-names></name><name name-style="western"><surname>Welzel</surname><given-names>J</given-names></name><name name-style="western"><surname>Geritz</surname><given-names>J</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>C</given-names></name><name name-style="western"><surname>Gold</surname><given-names>R</given-names></name><name name-style="western"><surname>Maetzler</surname><given-names>W</given-names></name><name name-style="western"><surname>Scherbaum</surname><given-names>R</given-names></name><name name-style="western"><surname>T&#246;nges</surname><given-names>L</given-names></name></person-group><article-title>Clinical and device-based predictors of improved experience of activities of daily living after a multidisciplinary inpatient treatment for people with parkinson&#8217;s disease: A cohort study</article-title><source>Therapeutic Advances in Neurological Disorders</source><year>2024</year><volume>17</volume><fpage>17562864241277157</fpage><pub-id pub-id-type="doi">10.1177/17562864241277157</pub-id><pub-id pub-id-type="pmid">39328922</pub-id><pub-id pub-id-type="pmcid">PMC11425784</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Oppermann, J., Tschentscher, V., Welzel, J., Geritz, J., Hansen, C., Gold, R., Maetzler, W., Scherbaum, R., &amp; T&#246;nges, L. (2024). Clinical and device-based predictors of improved experience of activities of daily living after a multidisciplinary inpatient treatment for people with parkinson&#8217;s disease: A cohort study. <italic toggle="yes">Therapeutic Advances in Neurological Disorders</italic>, <italic toggle="yes">17</italic>, 17562864241277157. 10.1177/17562864241277157<pub-id pub-id-type="pmid">39328922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17562864241277157</pub-id><pub-id pub-id-type="pmcid">PMC11425784</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scherbaum</surname><given-names>R</given-names></name><name name-style="western"><surname>Hartelt</surname><given-names>E</given-names></name><name name-style="western"><surname>Kinkel</surname><given-names>M</given-names></name><name name-style="western"><surname>Gold</surname><given-names>R</given-names></name><name name-style="western"><surname>Muhlack</surname><given-names>S</given-names></name><name name-style="western"><surname>T&#246;nges</surname><given-names>L</given-names></name></person-group><article-title>Parkinson&#8217;s disease multimodal complex treatment improves motor symptoms, depression and quality of life</article-title><source>Journal of Neurology</source><year>2020</year><volume>267</volume><issue>4</issue><fpage>954</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1007/s00415-019-09657-7</pub-id><pub-id pub-id-type="pmid">31797086</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Scherbaum, R., Hartelt, E., Kinkel, M., Gold, R., Muhlack, S., &amp; T&#246;nges, L. (2020). Parkinson&#8217;s disease multimodal complex treatment improves motor symptoms, depression and quality of life. <italic toggle="yes">Journal of Neurology</italic>, <italic toggle="yes">267</italic>(4), 954&#8211;965. 10.1007/s00415-019-09657-7<pub-id pub-id-type="pmid">31797086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-019-09657-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziegler</surname><given-names>K</given-names></name><name name-style="western"><surname>Fietzek</surname><given-names>UM</given-names></name><name name-style="western"><surname>Ceballos-Baumann</surname><given-names>AO</given-names></name></person-group><article-title>Multimodale Therapieangebote Bei der Parkinson-Krankheit</article-title><source>Nervenheilkunde</source><year>2025</year><volume>44</volume><issue>03</issue><fpage>86</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1055/a-2449-1461</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Ziegler, K., Fietzek, U. M., &amp; Ceballos-Baumann, A. O. (2025). Multimodale Therapieangebote Bei der Parkinson-Krankheit. <italic toggle="yes">Nervenheilkunde</italic>, <italic toggle="yes">44</italic>(03), 86&#8211;97. 10.1055/a-2449-1461</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steendam-Oldekamp</surname><given-names>E</given-names></name><name name-style="western"><surname>van Laar</surname><given-names>T</given-names></name></person-group><article-title>The effectiveness of inpatient rehabilitation in parkinson&#8217;s disease: A systematic review of recent studies</article-title><source>Journal of Parkinson&#8217;s Disease</source><year>2024</year><volume>14</volume><issue>s1</issue><fpage>S93</fpage><lpage>S112</lpage><pub-id pub-id-type="doi">10.3233/JPD-230271</pub-id><pub-id pub-id-type="pmid">38788087</pub-id><pub-id pub-id-type="pmcid">PMC11380234</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Steendam-Oldekamp, E., &amp; van Laar, T. (2024). The effectiveness of inpatient rehabilitation in parkinson&#8217;s disease: A systematic review of recent studies. <italic toggle="yes">Journal of Parkinson&#8217;s Disease</italic>, <italic toggle="yes">14</italic>(s1), S93&#8211;S112. 10.3233/JPD-230271<pub-id pub-id-type="pmid">38788087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JPD-230271</pub-id><pub-id pub-id-type="pmcid">PMC11380234</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lidstone</surname><given-names>SC</given-names></name><name name-style="western"><surname>Bayley</surname><given-names>M</given-names></name><name name-style="western"><surname>Lang</surname><given-names>AE</given-names></name></person-group><article-title>The evidence for multidisciplinary care in parkinson&#8217;s disease</article-title><source>Expert Review of Neurotherapeutics</source><year>2020</year><volume>20</volume><issue>6</issue><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1080/14737175.2020.1771184</pub-id><pub-id pub-id-type="pmid">32479209</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Lidstone, S. C., Bayley, M., &amp; Lang, A. E. (2020). The evidence for multidisciplinary care in parkinson&#8217;s disease. <italic toggle="yes">Expert Review of Neurotherapeutics</italic>, <italic toggle="yes">20</italic>(6), 539&#8211;549. 10.1080/14737175.2020.1771184<pub-id pub-id-type="pmid">32479209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737175.2020.1771184</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scherbaum</surname><given-names>R</given-names></name><name name-style="western"><surname>Moewius</surname><given-names>A</given-names></name><name name-style="western"><surname>Oppermann</surname><given-names>J</given-names></name><name name-style="western"><surname>Geritz</surname><given-names>J</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>C</given-names></name><name name-style="western"><surname>Gold</surname><given-names>R</given-names></name><name name-style="western"><surname>Maetzler</surname><given-names>W</given-names></name><name name-style="western"><surname>T&#246;nges</surname><given-names>L</given-names></name></person-group><article-title>Parkinson&#8217;s disease multimodal complex treatment improves gait performance: An exploratory wearable digital device-supported study</article-title><source>Journal of Neurology</source><year>2022</year><volume>269</volume><issue>11</issue><fpage>6067</fpage><lpage>6085</lpage><pub-id pub-id-type="doi">10.1007/s00415-022-11257-x</pub-id><pub-id pub-id-type="pmid">35864214</pub-id><pub-id pub-id-type="pmcid">PMC9553759</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Scherbaum, R., Moewius, A., Oppermann, J., Geritz, J., Hansen, C., Gold, R., Maetzler, W., &amp; T&#246;nges, L. (2022). Parkinson&#8217;s disease multimodal complex treatment improves gait performance: An exploratory wearable digital device-supported study. <italic toggle="yes">Journal of Neurology</italic>, <italic toggle="yes">269</italic>(11), 6067&#8211;6085. 10.1007/s00415-022-11257-x<pub-id pub-id-type="pmid">35864214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-022-11257-x</pub-id><pub-id pub-id-type="pmcid">PMC9553759</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Postuma</surname><given-names>RB</given-names></name><name name-style="western"><surname>Berg</surname><given-names>D</given-names></name><name name-style="western"><surname>Stern</surname><given-names>M</given-names></name><name name-style="western"><surname>Poewe</surname><given-names>W</given-names></name><name name-style="western"><surname>Olanow</surname><given-names>CW</given-names></name><name name-style="western"><surname>Oertel</surname><given-names>W</given-names></name><name name-style="western"><surname>Obeso</surname><given-names>J</given-names></name><name name-style="western"><surname>Marek</surname><given-names>K</given-names></name><name name-style="western"><surname>Litvan</surname><given-names>I</given-names></name><name name-style="western"><surname>Lang</surname><given-names>AE</given-names></name><name name-style="western"><surname>Halliday</surname><given-names>G</given-names></name><name name-style="western"><surname>Goetz</surname><given-names>CG</given-names></name><name name-style="western"><surname>Gasser</surname><given-names>T</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>B</given-names></name><name name-style="western"><surname>Chan</surname><given-names>P</given-names></name><name name-style="western"><surname>Bloem</surname><given-names>BR</given-names></name><name name-style="western"><surname>Adler</surname><given-names>CH</given-names></name><name name-style="western"><surname>Deuschl</surname><given-names>G</given-names></name></person-group><article-title>MDS clinical diagnostic criteria for parkinson&#8217;s disease: MDS-PD clinical diagnostic criteria</article-title><source>Movement Disorders</source><year>2015</year><volume>30</volume><issue>12</issue><fpage>1591</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1002/mds.26424</pub-id><pub-id pub-id-type="pmid">26474316</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., Halliday, G., Goetz, C. G., Gasser, T., Dubois, B., Chan, P., Bloem, B. R., Adler, C. H., &amp; Deuschl, G. (2015). MDS clinical diagnostic criteria for parkinson&#8217;s disease: MDS-PD clinical diagnostic criteria. <italic toggle="yes">Movement Disorders</italic>, <italic toggle="yes">30</italic>(12), 1591&#8211;1601. 10.1002/mds.26424<pub-id pub-id-type="pmid">26474316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.26424</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;gge</surname><given-names>F</given-names></name><name name-style="western"><surname>Kleinholdermann</surname><given-names>U</given-names></name><name name-style="western"><surname>Heun</surname><given-names>A</given-names></name><name name-style="western"><surname>Ollenschl&#228;ger</surname><given-names>M</given-names></name><name name-style="western"><surname>Hannink</surname><given-names>J</given-names></name><name name-style="western"><surname>Pedrosa</surname><given-names>DJ</given-names></name></person-group><article-title>Subthalamic 85 hz deep brain stimulation improves walking Pace and Stride length in parkinson&#8217;s disease patients</article-title><source>Neurological Research and Practice</source><year>2023</year><volume>5</volume><issue>1</issue><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s42466-023-00263-7</pub-id><pub-id pub-id-type="pmid">37559161</pub-id><pub-id pub-id-type="pmcid">PMC10413698</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">M&#252;gge, F., Kleinholdermann, U., Heun, A., Ollenschl&#228;ger, M., Hannink, J., &amp; Pedrosa, D. J. (2023). Subthalamic 85 hz deep brain stimulation improves walking pace and stride length in Parkinson&#8217;s disease patients. <italic toggle="yes">Neurological Research and Practice</italic>, <italic toggle="yes">5</italic>(1), 33. 10.1186/s42466-023-00263-7<pub-id pub-id-type="pmid">37559161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s42466-023-00263-7</pub-id><pub-id pub-id-type="pmcid">PMC10413698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peto</surname><given-names>V</given-names></name><name name-style="western"><surname>Jenkinson</surname><given-names>C</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>R</given-names></name><name name-style="western"><surname>Greenhall</surname><given-names>R</given-names></name></person-group><article-title>The development and validation of a short measure of functioning and well being for individuals with parkinson&#8217;s disease</article-title><source>Quality of Life Research</source><year>1995</year><volume>4</volume><issue>3</issue><fpage>241</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1007/BF02260863</pub-id><pub-id pub-id-type="pmid">7613534</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Peto, V., Jenkinson, C., Fitzpatrick, R., &amp; Greenhall, R. (1995). The development and validation of a short measure of functioning and well being for individuals with parkinson&#8217;s disease. <italic toggle="yes">Quality of Life Research</italic>, <italic toggle="yes">4</italic>(3), 241&#8211;248. 10.1007/BF02260863<pub-id pub-id-type="pmid">7613534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02260863</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Podsiadlo</surname><given-names>D</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>S</given-names></name></person-group><article-title>The timed up &amp; go: A test of basic functional mobility for frail elderly persons</article-title><source>Journal of the American Geriatrics Society</source><year>1991</year><volume>39</volume><issue>2</issue><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.1991.tb01616.x</pub-id><pub-id pub-id-type="pmid">1991946</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Podsiadlo, D., &amp; Richardson, S. (1991). The timed up &amp; go: A test of basic functional mobility for frail elderly persons. <italic toggle="yes">Journal of the American Geriatrics Society</italic>, <italic toggle="yes">39</italic>(2), 142&#8211;148. 10.1111/j.1532-5415.1991.tb01616.x<pub-id pub-id-type="pmid">1991946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.1991.tb01616.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez-Martin,P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., Dubois, B., Holloway, R., Jankovic,J., Kulisevsky, J., Lang, A. E., Lees, A., Leurgans, S., LeWitt, P. A., Nyenhuis,D., &#8230; Movement Disorder Society UPDRS Revision Task Force. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson&#8217;s Disease Rating Scale (MDS-UPDRS):Scale presentation and clinimetric testing results. <italic toggle="yes">Movement Disorders: Official Journal of the Movement Disorder Society</italic>, <italic toggle="yes">23</italic>(15), 2129&#8211;2170. 10.1002/mds.22340.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.22340</pub-id><pub-id pub-id-type="pmid">19025984</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barth</surname><given-names>J</given-names></name><name name-style="western"><surname>Oberndorfer</surname><given-names>C</given-names></name><name name-style="western"><surname>Pasluosta</surname><given-names>C</given-names></name><name name-style="western"><surname>Sch&#252;lein</surname><given-names>S</given-names></name><name name-style="western"><surname>Gassner</surname><given-names>H</given-names></name><name name-style="western"><surname>Reinfelder</surname><given-names>S</given-names></name><name name-style="western"><surname>Kugler</surname><given-names>P</given-names></name><name name-style="western"><surname>Schuldhaus</surname><given-names>D</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>J</given-names></name><name name-style="western"><surname>Klucken</surname><given-names>J</given-names></name><name name-style="western"><surname>Eskofier</surname><given-names>B</given-names></name></person-group><article-title>Stride segmentation during free walk movements using Multi-Dimensional subsequence dynamic time warping on inertial sensor data</article-title><source>Sensors (Basel, Switzerland)</source><year>2015</year><volume>15</volume><issue>3</issue><fpage>6419</fpage><lpage>6440</lpage><pub-id pub-id-type="doi">10.3390/s150306419</pub-id><pub-id pub-id-type="pmid">25789489</pub-id><pub-id pub-id-type="pmcid">PMC4435165</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Barth, J., Oberndorfer, C., Pasluosta, C., Sch&#252;lein, S., Gassner, H., Reinfelder, S., Kugler, P., Schuldhaus, D., Winkler, J., Klucken, J., &amp; Eskofier, B. (2015). Stride segmentation during free walk movements using multi-dimensional subsequence dynamic time warping on inertial sensor data. <italic toggle="yes">Sensors (Basel, Switzerland)</italic>, <italic toggle="yes">15</italic>(3), 6419&#8211;6440. 10.3390/s150306419<pub-id pub-id-type="pmid">25789489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/s150306419</pub-id><pub-id pub-id-type="pmcid">PMC4435165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Hannink, J., Ollenschl&#228;ger, M., Kluge, F., Roth, N., Klucken, J., &amp; Eskofier, B. M. (2017). Benchmarking foot trajectory estimation methods for mobile gait analysis. <italic toggle="yes">Sensors</italic>, <italic toggle="yes">17</italic>(9), 1940. 10.3390/s17091940<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/s17091940</pub-id><pub-id pub-id-type="pmcid">PMC5621093</pub-id><pub-id pub-id-type="pmid">28832511</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing. <ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link></mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peto</surname><given-names>V</given-names></name></person-group><article-title>Determining minimally important differences for the PDQ-39 parkinson&#8217;s disease questionnaire</article-title><source>Age and Ageing</source><year>2001</year><volume>30</volume><issue>4</issue><fpage>299</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1093/ageing/30.4.299</pub-id><pub-id pub-id-type="pmid">11509307</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Peto, V. (2001). Determining minimally important differences for the PDQ-39 parkinson&#8217;s disease questionnaire. <italic toggle="yes">Age and Ageing</italic>, <italic toggle="yes">30</italic>(4), 299&#8211;302. 10.1093/ageing/30.4.299<pub-id pub-id-type="pmid">11509307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ageing/30.4.299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horv&#225;th</surname><given-names>K</given-names></name><name name-style="western"><surname>Aschermann</surname><given-names>Z</given-names></name><name name-style="western"><surname>&#193;cs</surname><given-names>P</given-names></name><name name-style="western"><surname>Deli</surname><given-names>G</given-names></name><name name-style="western"><surname>Janszky</surname><given-names>J</given-names></name><name name-style="western"><surname>Komoly</surname><given-names>S</given-names></name><name name-style="western"><surname>Bal&#225;zs</surname><given-names>&#201;</given-names></name><name name-style="western"><surname>Tak&#225;cs</surname><given-names>K</given-names></name><name name-style="western"><surname>Kar&#225;di</surname><given-names>K</given-names></name><name name-style="western"><surname>Kov&#225;cs</surname><given-names>N</given-names></name></person-group><article-title>Minimal clinically important difference on the motor examination part of MDS-UPDRS</article-title><source>Parkinsonism &amp; Related Disorders</source><year>2015</year><volume>21</volume><issue>12</issue><fpage>1421</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2015.10.006</pub-id><pub-id pub-id-type="pmid">26578041</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Horv&#225;th, K., Aschermann, Z., &#193;cs, P., Deli, G., Janszky, J., Komoly, S., Bal&#225;zs, &#201;., Tak&#225;cs, K., Kar&#225;di, K., &amp; Kov&#225;cs, N. (2015). Minimal clinically important difference on the motor examination part of MDS-UPDRS. <italic toggle="yes">Parkinsonism &amp; Related Disorders</italic>, <italic toggle="yes">21</italic>(12), 1421&#8211;1426. 10.1016/j.parkreldis.2015.10.006<pub-id pub-id-type="pmid">26578041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2015.10.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Santos Garc&#237;a, D., De Deus Fonticoba, T., Su&#225;rez Castro, E., Borru&#233;, C., Mata, M.,Solano Vila, B., Cots Foraster, A., &#193;lvarez Sauco, M., Rodr&#237;guez P&#233;rez, A. B., Vela,L., Mac&#237;as, Y., Escalante, S., Esteve, P., Revert&#233; Villarroya, S., Cubo, E., Casas,E., Arnaiz, S., Carrillo Padilla, F., Pueyo Morlans, M., &#8230; Villar, M. D. (2019). Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson&#8217;s disease patients: Results from the COPPADIS study cohort. <italic toggle="yes">Parkinsonism &amp; Related Disorders</italic>, <italic toggle="yes">66</italic>, 151&#8211;157. 10.1016/j.parkreldis.2019.07.031.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2019.07.031</pub-id><pub-id pub-id-type="pmid">31409572</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cronin</surname><given-names>P</given-names></name><name name-style="western"><surname>Collins</surname><given-names>LM</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>AM</given-names></name></person-group><article-title>Impacts of gait freeze on quality of life in parkinson&#8217;s disease, from the perspectives of patients and their carers</article-title><source>Irish Journal of Medical Science (1971 -)</source><year>2024</year><volume>193</volume><issue>4</issue><fpage>2041</fpage><lpage>2050</lpage><pub-id pub-id-type="doi">10.1007/s11845-024-03673-x</pub-id><pub-id pub-id-type="pmcid">PMC11294397</pub-id><pub-id pub-id-type="pmid">38639839</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Cronin, P., Collins, L. M., &amp; Sullivan, A. M. (2024). Impacts of gait freeze on quality of life in parkinson&#8217;s disease, from the perspectives of patients and their carers. <italic toggle="yes">Irish Journal of Medical Science (1971 -)</italic>, <italic toggle="yes">193</italic>(4), 2041&#8211;2050. 10.1007/s11845-024-03673-x<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11845-024-03673-x</pub-id><pub-id pub-id-type="pmcid">PMC11294397</pub-id><pub-id pub-id-type="pmid">38639839</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirelman</surname><given-names>A</given-names></name><name name-style="western"><surname>Bonato</surname><given-names>P</given-names></name><name name-style="western"><surname>Camicioli</surname><given-names>R</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>TD</given-names></name><name name-style="western"><surname>Giladi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>JL</given-names></name><name name-style="western"><surname>Hass</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Hausdorff</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pelosin</surname><given-names>E</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>QJ</given-names></name></person-group><article-title>Gait impairments in parkinson&#8217;s disease</article-title><source>The Lancet Neurology</source><year>2019</year><volume>18</volume><issue>7</issue><fpage>697</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(19)30044-4</pub-id><pub-id pub-id-type="pmid">30975519</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Mirelman, A., Bonato, P., Camicioli, R., Ellis, T. D., Giladi, N., Hamilton, J. L., Hass, C. J., Hausdorff, J. M., Pelosin, E., &amp; Almeida, Q. J. (2019). Gait impairments in parkinson&#8217;s disease. <italic toggle="yes">The Lancet Neurology</italic>, <italic toggle="yes">18</italic>(7), 697&#8211;708. 10.1016/S1474-4422(19)30044-4<pub-id pub-id-type="pmid">30975519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(19)30044-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianchini</surname><given-names>E</given-names></name><name name-style="western"><surname>Galli</surname><given-names>S</given-names></name><name name-style="western"><surname>Alborghetti</surname><given-names>M</given-names></name><name name-style="western"><surname>De Carolis</surname><given-names>L</given-names></name><name name-style="western"><surname>Zampogna</surname><given-names>A</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>C</given-names></name><name name-style="western"><surname>Vuillerme</surname><given-names>N</given-names></name><name name-style="western"><surname>Suppa</surname><given-names>A</given-names></name><name name-style="western"><surname>Pontieri</surname><given-names>FE</given-names></name></person-group><article-title>Four days are enough to provide a reliable daily step count in mild to moderate parkinson&#8217;s disease through a commercial smartwatch</article-title><source>Sensors (Basel, Switzerland)</source><year>2023</year><volume>23</volume><issue>21</issue><fpage>8971</fpage><pub-id pub-id-type="doi">10.3390/s23218971</pub-id><pub-id pub-id-type="pmid">37960670</pub-id><pub-id pub-id-type="pmcid">PMC10649244</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Bianchini, E., Galli, S., Alborghetti, M., De Carolis, L., Zampogna, A., Hansen, C., Vuillerme, N., Suppa, A., &amp; Pontieri, F. E. (2023). Four days are enough to provide a reliable daily step count in mild to moderate parkinson&#8217;s disease through a commercial smartwatch. <italic toggle="yes">Sensors (Basel, Switzerland)</italic>, <italic toggle="yes">23</italic>(21), 8971. 10.3390/s23218971<pub-id pub-id-type="pmid">37960670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/s23218971</pub-id><pub-id pub-id-type="pmcid">PMC10649244</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atrsaei</surname><given-names>A</given-names></name><name name-style="western"><surname>Corr&#224;</surname><given-names>MF</given-names></name><name name-style="western"><surname>Dadashi</surname><given-names>F</given-names></name><name name-style="western"><surname>Vila-Ch&#227;</surname><given-names>N</given-names></name><name name-style="western"><surname>Maia</surname><given-names>L</given-names></name><name name-style="western"><surname>Mariani</surname><given-names>B</given-names></name><name name-style="western"><surname>Maetzler</surname><given-names>W</given-names></name><name name-style="western"><surname>Aminian</surname><given-names>K</given-names></name></person-group><article-title>Gait speed in clinical and daily living assessments in parkinson&#8217;s disease patients: Performance versus capacity</article-title><source>Npj Parkinson&#8217;s Disease</source><year>2021</year><volume>7</volume><issue>1</issue><fpage>24</fpage><pub-id pub-id-type="doi">10.1038/s41531-021-00171-0</pub-id><pub-id pub-id-type="pmid">33674597</pub-id><pub-id pub-id-type="pmcid">PMC7935857</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Atrsaei, A., Corr&#224;, M. F., Dadashi, F., Vila-Ch&#227;, N., Maia, L., Mariani, B., Maetzler, W., &amp; Aminian, K. (2021). Gait speed in clinical and daily living assessments in parkinson&#8217;s disease patients: Performance versus capacity. <italic toggle="yes">Npj Parkinson&#8217;s Disease</italic>, <italic toggle="yes">7</italic>(1), 24. 10.1038/s41531-021-00171-0<pub-id pub-id-type="pmid">33674597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-021-00171-0</pub-id><pub-id pub-id-type="pmcid">PMC7935857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sica</surname><given-names>M</given-names></name><name name-style="western"><surname>Tedesco</surname><given-names>S</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>C</given-names></name><name name-style="western"><surname>Kenny</surname><given-names>L</given-names></name><name name-style="western"><surname>Moore</surname><given-names>K</given-names></name><name name-style="western"><surname>Timmons</surname><given-names>S</given-names></name><name name-style="western"><surname>Barton</surname><given-names>J</given-names></name><name name-style="western"><surname>O&#8217;Flynn</surname><given-names>B</given-names></name><name name-style="western"><surname>Komaris</surname><given-names>DS</given-names></name></person-group><article-title>Continuous home monitoring of parkinson&#8217;s disease using inertial sensors: A systematic review</article-title><source>PloS One</source><year>2021</year><volume>16</volume><issue>2</issue><fpage>e0246528</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0246528</pub-id><pub-id pub-id-type="pmid">33539481</pub-id><pub-id pub-id-type="pmcid">PMC7861548</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Sica, M., Tedesco, S., Crowe, C., Kenny, L., Moore, K., Timmons, S., Barton, J., O&#8217;Flynn, B., &amp; Komaris, D. S. (2021). Continuous home monitoring of parkinson&#8217;s disease using inertial sensors: A systematic review. <italic toggle="yes">PloS One</italic>, <italic toggle="yes">16</italic>(2), e0246528. 10.1371/journal.pone.0246528<pub-id pub-id-type="pmid">33539481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0246528</pub-id><pub-id pub-id-type="pmcid">PMC7861548</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>